NeuroBo Pharmaceuticals, Inc. (NRBO)

NeuroBo Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	15.99	22.44	33.36	16.39	10.09	13.92
Cash & Cash Equivalents	15.99	22.44	33.36	16.39	10.09	13.92
Cash Growth	-48.11%	-32.76%	103.60%	62.42%	-27.54%	389.38%
Other Current Assets	0.78	0.08	0.17	0.2	0.59	0.2
Total Current Assets	16.76	22.51	33.53	16.58	10.68	14.12
Property, Plant & Equipment	0.23	0.25	0	0.22	0.29	0.35
Other Long-Term Assets	0.02	0.02	0	0	0	0
Total Long-Term Assets	0.25	0.27	0	0.22	0.29	0.35
Total Assets	17.02	22.78	33.53	16.8	10.97	14.47
Accounts Payable	2.08	0.82	0.71	0.83	2.58	0.64
Current Debt	0.07	0.07	0	0.03	0.02	0.02
Other Current Liabilities	4.68	5.07	11.08	1.3	1.1	1.42
Total Current Liabilities	6.83	5.96	11.78	2.16	3.7	2.08
Long-Term Debt	0.12	0.14	0	0.05	0.07	0.09
Total Long-Term Liabilities	0.12	0.14	0	0.05	0.07	0.09
Total Liabilities	6.94	6.1	11.78	2.2	3.77	2.18
Total Debt	0.19	0.2	0	0.07	0.09	0.12
Debt Growth	-	-	-	-24.47%	-18.97%	-17.73%
Retained Earnings	-114.98	-108.27	-95.8	-81.83	-66.54	-36.87
Comprehensive Income	0	0	0	0	0.01	0.01
Shareholders' Equity	10.08	16.69	21.75	14.6	7.2	12.29
Net Cash / Debt	15.8	22.23	33.36	16.32	10	13.81
Net Cash / Debt Growth	-48.72%	-33.37%	104.49%	63.24%	-27.61%	410.61%
Net Cash Per Share	3.10	4.38	103.71	169.20	147.93	634.37
Working Capital	9.94	16.55	21.75	14.43	6.99	12.04
Book Value Per Share	1.98	3.29	67.61	151.38	106.61	564.75

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).